TABLE 2.
Effect of antimicrobial compounds on growth of the ropB family mutants
| Strain | Log growth reductiona |
MICb |
||||
|---|---|---|---|---|---|---|
| PCA |
Erythromycin |
|||||
| 1.5 mM DOC | 0.35 mM SDS | TY | VMM | TY | VMM | |
| VF39SM | 0.191 ± 0.057 | 0.263 ± 0.112 | 5.5 | 6.0 | 8.83 × 10−3 | 0.027 |
| DF33 (ropB mutant) | 4.85 ± 1.22* | 3.86 ± 1.21* | 4.5 | 5.5 | 1.36 × 10−3 | 0.010 |
| DF33 (ropB mutant) + pDF37 | 0.351 ± 0.163 | 0.708 ± 0.386 | 5.5 | 6.0 | 8.83 × 10−3 | 0.027 |
| DF15 (ropB2 mutant) | 0.103 ± 0.179 | 0.101 ± 0.355 | 5.5 | 6.0 | 8.83 × 10−3 | 0.027 |
| DF42 (ropB3 mutant) | 0.123 ± 0.251 | 0.026 ± 0.131 | 5.5 | 6.0 | 8.83 × 10−3 | 0.027 |
a
Growth reduction values were calculated by subtracting the number of log CFU/ml grown on TY plus detergent from the number of log CFU/ml grown on TY. Data are presented as the average results ± standard deviations from at least three trials. An asterisk indicates a significant difference in growth between the wild type and the mutant (t test; P of <0.01).
b
Strains were grown in either TY or VMM broth with various concentrations of PCA or erythromycin. MICs are presented in mM and are representative values from a minimum of three separate replicates.